Institute Governance

Management

Pr Hugues DE THÉ

Hugues de Thé has been the Director of the IHU Leukemia Institute Paris Saint-Louis since 2023.

Hugues de Thé, M.D., Ph.D., is a Professor of Molecular Oncology at the Collège de France and a physician at Saint-Louis Hospital in Paris. After making major contributions to retinoic acid signaling during his medical and scientific training (MD/PhD), he played a key role in the discovery of the PML/RARA oncoprotein, which is responsible for acute promyelocytic leukemia. Since then, he has been studying the mechanisms by which PML/RARA drives leukemogenesis, as well as the molecular basis for the remarkable clinical response to retinoic acid and arsenic.

Jean SOULIER

Jean Soulier is the Deputy Director of the Institute.

Jean Soulier, M.D., Ph.D., is a Professor of Hematology affiliated with Université Paris Cité, the Assistance Publique–Hôpitaux de Paris (AP-HP), and INSERM. He also heads the Biological Hematology Laboratory at Saint‑Louis Hospital, as well as the INSERM/CNRS Research Unit UMR 1342.

Jean Soulier investigates the genetic mechanisms underlying the progression of bone marrow failure disorders such as Fanconi anemia, myelodysplastic syndromes, and acute leukemias.

He also studies oncogenic subtypes and clonal evolution to better understand tumor progression and relapse in these hematopoietic cancers.

Since January 1, 2025, Jean Soulier has been the Director of the Saint-Louis Research Institute.

Stéphanie CHAMBAUD

Stéphanie Chambaud is the Secretary General of the Institute. In this role, she coordinates all administrative activities, supports the implementation of the institutional strategy, and serves as a liaison between decision-making bodies, operational teams, and external partners.

A trained lawyer specializing in public law, Stéphanie Chambaud began her career in local public service and has since held various positions within AP-HP, notably in the fields of clinical research and human resources.

The IHU Team

The IHU Team supports the Director of the Institute by managing day-to-day operations and implementing the overall strategy defined by the Supervisory Board, according to a three-year roadmap. It develops scientific projects, proposes corrective actions, and evaluates the strategy. The team organizes project presentations during internal calls for proposals and monitors performance indicators.

The team is composed of:

Hervé DOMBRET

Hervé Dombret is a key figure at the IHU Leukemia Institute Paris Saint-Louis, which he helped to establish as coordinator of IHU-B THEMA. He led the Adult Hematology Department at Saint-Louis Hospital (AP-HP) from 2005 to 2022 and directed the Saint-Louis Research Institute until 2024.

His research focuses on acute myeloid and lymphoblastic leukemias, and he serves as president of several leukemia research associations and groups. Author of over 450 scientific articles, he is also active in numerous international hematology societies and serves as an associate editor for the journal Blood. He is recognized for his extensive scientific contributions, with an H-index of 102.

Lionel ADÈS

Professor Lionel Adès is a recognized specialist in medical oncology, with a particular focus on rare cancers and innovative therapies. He is a Professor of Oncology at Université Paris-Saclay and a hospital practitioner within AP-HP. His research focuses on tumor biology and the optimization of anticancer treatments, particularly in the field of targeted therapies.

He is also involved in several international clinical trials for the development of new cancer drugs.
Professor Adès is an active member of the scientific community, participating in various oncology associations and research committees.

Françoise PFLUMIO

Françoise Pflumio is a leading researcher in cell biology and biotherapy, specializing in stem cells and gene therapies. She works at the CEA (French Alternative Energies and Atomic Energy Commission), where her research primarily focuses on the application of stem cells in the treatment of hematological diseases.

She has made significant contributions to the understanding of cellular differentiation mechanisms and the development of new therapeutic strategies. Françoise Pflumio is also involved in developing innovative therapies for the treatment of leukemia and other blood disorders. Her work is regularly published in renowned international journals.

Alexandre PUISSANT

Alexandre Puissant is a researcher at Inserm, specializing in oncology and molecular biology. His work focuses on the molecular mechanisms involved in cancers, particularly leukemias, and the development of new targeted therapies.

He has contributed to the identification of novel therapeutic targets for cancers resistant to conventional treatments. His research also examines the interactions between tumor cells and their microenvironment.

Alexandre Puissant is involved in numerous international projects aimed at improving cancer treatments.

Charlotte BOUQUEREL

Charlotte is the Head of Strategic Development at the Institute.

Trained as an engineer, she then completed a CIFRE doctoral thesis at the Curie Institute, focusing on the impact of hypoxia in the tumor microenvironment and resistance to anticancer treatments, through the development of innovative models.

The Supervisory Board

The Supervisory Board, chaired by Jean-Patrick LAJONCHÈRE, is composed of eight ex-officio members representing the Founding Institutions (Université Paris Cité, AP-HP, INSERM, and Collège de France), one representative from the Université Paris Cité Foundation (Professor Gérard FRIEDLANDER), six qualified individuals (Claire BIOT, Professor Stanislas LYONNET, Pauline DE BRETEUIL, Ali SAIB, Nathalie VAROQUEAUX) from whom the Chair is selected, one representative of the researchers (Françoise PFLUMIO), and one representative of the users (Stéphanie FUGAIN).

Its main responsibilities are to oversee the Institute’s activities and projects and to approve budgets, ensuring, in particular, the proper management of resources.

Jean-Patrick LAJONCHÈRE

Gérard FRIEDLANDER

Claire BIOT

Stanislas LYONNET

Nathalie VAROQUEAUX

Ali SAIB

Pauline DE BRETEUIL

Françoise PFLUMIO

Stéphanie FUGAIN

Nicolas JEANJEAN

The Scientific Advisory Board (SAB)

Consulted on the Institute’s major scientific directions, the SAB is also responsible for evaluating team activities and selecting new teams for potential recruitment.

Courtney DINARDO – University of Texas MD Anderson Cancer Center, Houston, USA

Timothy LEY – Oncology Division, Washington University, St. Louis, USA

Emmanuelle PASSEGUÉ – Columbia University Irving Medical Center, New York City, USA

Paresh VYAS – MRC Weatherall Institute of Molecular Medicine, Oxford, UK

Mark DAWSON – Peter MacCallum Cancer Center, Melbourne, Australia

Marc RAAIJMAKERS – Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands

Management

The IHU Team

The Supervisory Board

The Scientific Advisory Board (SAB)

Follow our actions by subscribing to the institute's newsletter